Bluecross has reached an agreement with Nant Health to reimburse for GPS cancer test which includes full genome sequencing of tumour and also RNA and protein quantification to provide personalised treatment options.

Fine print to note is that this reimbursement is for a small number of rare cancers or metastatic cancers with unknown primary tumours or those cases where other treatments have failed. Still this is a good start for precision medicine.

https://www.genomeweb.com/scan/some-coverage?utm_content=buffer52c10&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer